Kohjin Bio Co., Ltd.
177A・Growth Market・Chemicals
Tissue Culture Business
Core business responsible for the development, manufacturing, and sale of cell culture media for regenerative medicine and immunotherapy applications
| Period | Current | Previous | Change |
|---|---|---|---|
| Net sales (FY2026 full year, ending March 2026) | ¥2,540 million | ¥2,269 million | ↑ |
| Segment profit (operating profit) (FY2026 full year, ending March 2026) | ¥946 million | ¥765 million | ↑ |
| Net sales year-on-year change rate (FY2026 full year, ending March 2026) | +11.9% | － | ↑ |
| Segment profit year-on-year change rate (FY2026 full year, ending March 2026) | +23.7% | － | ↑ |
| Depreciation expense (FY2026 full year, ending March 2026) | ¥74 million | ¥83 million | ↓ |
Business Details
The company develops, manufactures, and sells cell culture media (basal media, serum-free media) for the purpose of proliferating human, animal, and insect cells. Its main customers are universities, companies, and medical institutions both in Japan and overseas. Serum-free media (KBM ADSC Series, KBM500 Series, etc.) are the mainstay products, with expansion into industrial applications for regenerative medicine, antibody drugs, and gene therapy. The company also engages in OEM products and contract manufacturing, with expanded sales to key customers driving revenue growth. It also collaborates with its equity-method affiliate, Ajinomoto Cambrex Bio Corporation.
Recent Overview
Double-digit growth in both sales and profit driven by strong OEM media orders, the group's only segment with increased revenue and profit
In the full fiscal year FY2026 (ending March 2026), the Tissue Culture Business achieved net sales of ¥2,540 million (up 11.9% year on year) and segment profit of ¥946 million (up 23.7% year on year), making it the only segment with both increased revenue and profit while the group as a whole experienced declines in both. Demand for cell culture media remained firm, supported by continued progress in research, development, and clinical trials in the regenerative medicine and cell therapy fields both domestically and overseas, with particularly strong orders for OEM media. This segment functioned as a stable revenue base supporting overall company performance.
Key Products
Growth Drivers
- Sustained increase in demand for cell culture media accompanying expansion of the domestic and overseas regenerative medicine and cell therapy markets
- Expansion of orders for OEM media and contract manufacturing projects (sales to key customers drove revenue growth in FY2026, ending March 2026)
- Pursuit of further revenue growth through expanded transactions with domestic and overseas research institutions and pharmaceutical companies
- Growing demand for CD media (for CHO cells, etc.) for industrial applications such as antibody drugs and CAR-T cells
- Establishment of a mass-supply system through development of powdered media and construction of dedicated manufacturing facilities
- Strengthening of a stable supply system centered on OEM products
Risks
- Intensifying competition in performance and pricing due to entry of local companies in Asia (particularly China)
- Impact on sales to China from geopolitical risks such as deteriorating Japan-China relations
- Risk that growth in the regenerative medicine market is affected by trends in R&D investment and the regulatory environment
- Cash flow pressure risk associated with capital expenditures such as land acquisition for new warehouse and factory construction (¥969 million spent on acquisition of tangible fixed assets in FY2026, ending March 2026)
- Risk of changes in trading terms or reduced orders in cases of high dependence on sales to key customers
Last updated: June 23, 2026